tradmap

COAG Hemab Therapeutics Holdings, Inc.

$29.17 +10.58%

Healthcare · Biological Products, (No Diagnostic Substances)

Hemab Therapeutics Holdings, Inc. (COAG) is a healthcare company in the Biological Products, (No Diagnostic Substances) industry, with a market capitalization of $1.4 billion. Shares last traded at $29.17, 20.3% below their 52-week high.

Market Cap
$1.4B
Shares Out
46.7M
EPS (TTM)
P/E Ratio
P/S Ratio
P/B Ratio
Dividend / Share
Dividend Yield
52-Week High
$36.61
52-Week Low
$23.50
Volume
15,801
Avg Vol (3m)
21,778.059

Performance

1W
+7.34%
1M
+16.03%
3M
6M
YTD
-10.25%
1Y

Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.

Technicals

RSI (14)
54.37
SMA (50)
SMA (200)
Price vs SMA50
Price vs SMA200
ATR (14)
$2.40

Recent earnings

PeriodEPS (diluted)Reported
Q1 2026 $-23.98 2026-05-21
Q1 2026 $-16.18 2026-05-21

Full earnings history →

Biological Products, (No Diagnostic Substances) peers

COAG vs 14 industry peers (Biological Products, (No Diagnostic Substances)), by market cap.

1–14 of 14
AMGNAmgen$182.1B23.624.9621.0%-1.27%
GILDGilead Sciences$153.5B18.045.2128.9%-1.46%
RVMDRevolution Medicines, Inc.$34.6B-30.62+3.14%
BIIBBiogen$29.0B22.442.9313.1%-1.15%
MRNAModerna$25.4B-8.99+3.22%
NBIXNeurocrine Biosciences Inc$15.9B33.245.5616.7%-0.48%
EXELExelixis, Inc.$13.1B16.685.6233.7%-1.04%
KRYSKrystal Biotech, Inc.$10.2B50.0226.3352.6%+1.68%
TECHBio-Techne$9.1B123.617.446.0%+5.36%
HALOHalozyme Therapeutics, Inc.$8.1B25.675.8222.7%-0.03%
IBRXImmunitybio, Inc.$7.7B-21.87+5.01%
RGENRepligen Corp$7.4B152.2710.086.6%-1.20%
KYMRKymera Therapeutics, Inc.$7.4B23.88+0.44%
PCVXVaxcyte, Inc.$7.4B-9688.00+1.57%

Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.